Gilead Sciences Sale of investments increased by 641.2% to $2.52B in Q1 2026 compared to the prior quarter. Over 3 years (FY 2021 to FY 2025), Sale of investments shows an upward trend with a 5.4% CAGR.
High proceeds indicate active portfolio management or a need for liquidity; low proceeds suggest a buy-and-hold strategy.
This represents the cash proceeds received from the sale of fixed-maturity and other investment securities classified as...
Standard for insurance companies with large investment portfolios; highly dependent on market conditions.
investing_proceeds_from_sale_of_available_for_sale_secur_6e0764| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $191.00M | $255.00M | $224.00M | $119.00M | $204.00M | $47.00M | $42.00M | $167.00M | $150.00M | $95.00M | $98.00M | $2.27B | $0.00 | $295.00M | $219.00M | $340.00M | $2.52B |
| QoQ Change | — | +33.5% | -12.2% | -46.9% | +71.4% | -77.0% | -10.6% | +297.6% | -10.2% | -36.7% | +3.2% | >999% | -100.0% | — | -25.8% | +55.3% | +641.2% |
| YoY Change | — | — | — | — | +6.8% | -81.6% | -81.3% | +40.3% | -26.5% | +102.1% | +133.3% | >999% | -100.0% | — | — | — | — |